New drug shows promise for schizophrenia psychosis

NCT ID NCT01499563

Completed Symptom relief Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 31 times

Summary

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during a sudden worsening of psychosis. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or another antipsychotic. The main goal was to measure changes in symptom severity using a standard rating scale over 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Clinical Site

Little Rock, Arkansas, United States
Clinical Site

Garden Grove, California, United States
Clinical Site

Atlanta, Georgia, United States
Clinical Site

Rockville, Maryland, United States
Clinical Site

St Louis, Missouri, United States
Clinical Site

Willingboro, New Jersey, United States
Clinical Site

Philadelphia, Pennsylvania, United States
Clinical Site

Austin, Texas, United States

Conditions

Explore the condition pages connected to this study.

SCHIZOPHRENIA